MELE, GIUSEPPE
 Distribuzione geografica
Continente #
AS - Asia 541
NA - Nord America 274
EU - Europa 193
SA - Sud America 182
AF - Africa 22
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 1.214
Nazione #
US - Stati Uniti d'America 246
SG - Singapore 209
BR - Brasile 142
VN - Vietnam 109
CN - Cina 98
IT - Italia 79
HK - Hong Kong 38
FR - Francia 24
DE - Germania 22
FI - Finlandia 16
AR - Argentina 14
MX - Messico 14
KR - Corea 13
EC - Ecuador 12
IN - India 12
IQ - Iraq 10
BD - Bangladesh 9
GB - Regno Unito 9
RU - Federazione Russa 9
AT - Austria 8
TR - Turchia 7
UA - Ucraina 7
ZA - Sudafrica 7
PK - Pakistan 6
ID - Indonesia 5
VE - Venezuela 5
CA - Canada 4
PL - Polonia 4
SA - Arabia Saudita 4
UZ - Uzbekistan 4
AE - Emirati Arabi Uniti 3
CZ - Repubblica Ceca 3
DO - Repubblica Dominicana 3
ES - Italia 3
MA - Marocco 3
MY - Malesia 3
CL - Cile 2
CO - Colombia 2
CR - Costa Rica 2
DZ - Algeria 2
EG - Egitto 2
ET - Etiopia 2
JP - Giappone 2
KE - Kenya 2
KG - Kirghizistan 2
NL - Olanda 2
PA - Panama 2
PE - Perù 2
PH - Filippine 2
TN - Tunisia 2
AO - Angola 1
AU - Australia 1
AZ - Azerbaigian 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BS - Bahamas 1
CH - Svizzera 1
GT - Guatemala 1
HN - Honduras 1
HR - Croazia 1
IE - Irlanda 1
IL - Israele 1
JO - Giordania 1
MD - Moldavia 1
PY - Paraguay 1
RO - Romania 1
SE - Svezia 1
SN - Senegal 1
TW - Taiwan 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 1.214
Città #
Singapore 99
San Jose 43
Ho Chi Minh City 42
Florence 38
Hong Kong 37
Ashburn 31
Boardman 27
Beijing 25
Hefei 23
Dallas 21
Hanoi 21
Seoul 13
São Paulo 13
Lauterbourg 11
Los Angeles 11
Munich 10
New York 9
Helsinki 8
Milan 8
Shanghai 8
Rio de Janeiro 7
Mexico City 6
Vienna 6
Da Nang 5
Guayaquil 5
Haiphong 5
Lappeenranta 5
Porto Alegre 5
Quito 5
Sesto Fiorentino 5
Washington 5
Aracaju 4
Baghdad 4
Charlotte 4
Council Bluffs 4
Curitiba 4
Lahore 4
Noto 4
Orem 4
Santa Clara 4
Tashkent 4
Atlanta 3
Bari 3
Biên Hòa 3
Campinas 3
Chicago 3
Hillsboro 3
Johannesburg 3
Naples 3
Paris 3
Raipur 3
Santo Domingo 3
Thái Nguyên 3
Turku 3
Warsaw 3
Addis Ababa 2
Belo Horizonte 2
Bishkek 2
Bologna 2
Brooklyn 2
Buffalo 2
Bắc Giang 2
Bắc Ninh 2
Carney 2
Caxias do Sul 2
Chennai 2
Denver 2
Enfield 2
Fortaleza 2
Frankfurt am Main 2
Hưng Yên 2
Iporá 2
Juiz de Fora 2
Kyiv 2
Londrina 2
Montreal 2
Nairobi 2
New Delhi 2
Ninh Bình 2
Nuremberg 2
Puchong 2
Recife 2
Ribeirão Preto 2
Riyadh 2
Rome 2
San José 2
San Luis 2
Secaucus 2
Sharjah 2
Tokyo 2
Vĩnh Tường 2
Alvorada 1
Amman 1
Amsterdam 1
Angeles City 1
Ankara 1
Annaba 1
Asunción 1
Baku 1
Bandar Seri Begawan 1
Totale 720
Nome #
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients 123
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials 120
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study 108
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials 107
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials 104
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials 97
Daratumumab-based regimens for patients with multiple myeloma plus extramedullary plasmacytomas or paraskeletal plasmacytomas: initial follow-up of an Italian multicenter observational clinical experience 94
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials 93
Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study 82
Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials 76
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab‐, Elotuzumab‐, and Carfilzomib‐Based Triplet Regimens: A Multicenter Real‐World Analysis of 635 Patients 69
Lenalidomide maintenance after bortezomib, thalidomide and dexamethasone (VTD) induction and autologous stem cell transplantation: an Italian real-life study of 602 patients 67
REFINING HIGH-RISK MULTIPLE MYELOMA: ADVANCEMENTS IN GENOMIC, CLINICAL, AND PROGNOSTIC CRITERIA 67
Imaging in Plasma‐Cell Neoplasms: Italian Experts’ Recommendations 15
A nationwide Italian GIMEMA survey on tandem autologous stem cell transplantation for newly diagnosed multiple myeloma patients treated with daratumumab, bortezomib, thalidomide and dexamethasone 7
Totale 1.229
Categoria #
all - tutte 5.671
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.671


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/202311 0 0 0 0 0 0 7 0 0 0 4 0
2023/2024122 2 2 22 20 8 15 8 1 1 2 5 36
2024/2025283 2 18 5 10 16 16 10 22 39 36 34 75
2025/2026813 94 54 68 71 142 62 111 60 83 68 0 0
Totale 1.229